Misonix (Misonix) Total Current Assets : $59.27 Mil (As of Jun. 2021)

View and export this data going back to 2019. Start your Free Trial

What is Misonix Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Misonix's total current assets for the quarter that ended in Jun. 2021 was $59.27 Mil.

Misonix Total Current Assets Historical Data

The historical data trend for Misonix's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Total Current Assets Chart

Misonix Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Total Current Assets

Get a 7-Day Free Trial

22.60

21.86

21.39

64.72

59.27

Misonix Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Total Current Assets	Get a 7-Day Free Trial															64.72	61.76	58.38	58.15	59.27

Misonix Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Misonix's Total Current Assets for the fiscal year that ended in Jun. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	31.046	+	11.35	+	15.752	+	1.119
	=	59.27

Misonix's Total Current Assets for the quarter that ended in Jun. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	31.046	+	11.35	+	15.752	+	1.119
	=	59.27

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Misonix (NAS:MSON) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Misonix's Liquidation Value for the quarter that ended in Jun. 2021 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	31.046	-	63.661	+	0.75 * 11.35	+	0.5 * 15.752
=	-16.23

Misonix Total Current Assets Related Terms

Thank you for viewing the detailed overview of Misonix's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Misonix (Misonix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1938 New Highway, Farmingdale, NY, USA, 11735

Website

https://www.misonix.com

Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.

Executives

Paul A Laviolette	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz	officer: Chief Operating Officer	3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton	director	C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer	officer: Chief Financial Officer	3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe	director	C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub	officer: Sr. VP Wound	8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis	director, officer: CEO	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker	officer: SVP Sales - Surgical	4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley	officer: President	C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby	director	C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc	10 percent owner	2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p.	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc	10 percent owner	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p.	10 percent owner	C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p.	10 percent owner	3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104